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Abstract: We report an unusual case of intermittent episodes of cholestasis in a young patient. The
cholestatic attacks were preceded in each case by an infection and subsequent antibiotic therapies. After
ruling out many possible causes of cholestatic hepatitis, the differential diagnoses were a benign recurrent
intrahepatic cholestasis or a drug-induced liver injury. We discuss here the diagnostic approach and
interpretation of the genetic analysis.
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Introduction 
Cholestasis is caused by a failure of one or more steps involved in bile production and leads 
to an elevation of bile constituents in blood 1,2. Clinically, cholestasis is associated with 
elevated serum bile salts, jaundice and pruritus. Cholestasis may be acquired or inherited. 
The latter forms of cholestasis are rare clinical entities and may present as severe 
progressive familial intrahepatic cholestasis (PFIC), as benign recurrent intrahepatic 
cholestasis (BRIC) as well as different cholestatic syndromes ranging from gallstone disease 
and intrahepatic cholestasis of pregnancy to liver fibrosis and cirrhosis 3-5. Currently, 
mutations in several genes are known to cause inherited cholestatic syndromes by affecting 
canalicular bile formation: the best studied ones include ATP8B1 (encoding the canalicular 
aminophospholipid translocator ATP8B1 or FIC1), ABCB11 (encoding the canalicular bile 
salt export pump BSEP) and ABCB4 (encoding the canalicular phosphatidylcholine 
translocator MDR3). In addition mutations in TJP2 (encoding the tight junction protein 2 
TJP2, which is a cytosolic component of tight junctions), NR1H4 (encoding the transcription 
factor and bile salt sensor FXR) and MYO5B6 also lead to cholestatic syndromes, albeit at a 










A 16-year-old male Moroccan teenager presented to the emergency department with acute-
onset jaundice. The patient had been healthy until a few days before when he began to vomit 
repeatedly, presented with abdominal cramping and felt very fatigued. He sought medical 
care after noticing jaundice and developing severe pruritus.  
On physical examination the patient was deeply jaundiced, afebrile and normotensive. The 
abdomen was soft without tenderness. The rest of the examination was unremarkable; and 
there was no sign of encephalopathy.  
The blood results revealed a markedly elevated total bilirubin (264 μmol/l, ref < 17 μmol/l), 
with a conjugated fraction of 232 μmol/l (ref < 7 μmol/l), elevated alanine aminotransferase 
(149 U/l, ref < 40 U/l) and aspartate aminotransferase (52 U/l, ref < 40 U/l). In contrast to the 
markedly elevated alkaline phosphatase (534 U/l, ref < 130 U/l) and the raised bile acid (324 
μmol/l (ref < 10 μmol/l), the GGT was in the normal range (58 U/l, ref 50 U/l). Liver function 
was well preserved and there were no signs of systemic infection (Lab value Figure 1).  
Screening tests for viral hepatitis (A, B and C), as well as a HIV, were negative. There was 
no evidence for Wilson’s disease (normal ceruloplasmin and normal 24h urinary copper 
excretion), alpha-1 antitrypsin disease (MM phenotype), autoimmune hepatitis (no 
autoantibodies) or celiac disease. Ultrasound revealed a normal, but slightly enlarged liver 
with patent portal and hepatic veins and a normal hepatic artery Doppler. There was no 
splenomegaly.  
Over the next days bilirubin continued to rise prompting liver biopsy. This showed profound 
cholestasis with minimal inflammation. The copper in the liver biopsy was slightly elevated 
(111 μg/g, ref 10-35 μg/g), but below the diagnostic threshold of 350 μg/g. Nevertheless, an 
ocular slit-lamp examination was performed, but there was no evidence for Kayser-Fleischer 
rings. Furthermore, a mutation in the ATP7B Gen was excluded. Increased hepatic copper 
was interpreted to be secondary to cholestasis.  
Finally, a detailed history with the patient revealed that he was consuming cannabis on a 
regular basis and had repeatedly experimented with codeine syrup in the months preceding 
his clinical presentation. He rarely drank alcoholic beverages.  Cannabis and codeine use 
were confirmed on urinary testing. The patient was adopted, so that his family history was 
not available. 
Having ruled out many possible causes of the cholestatic hepatitis, the initial hypothesis was 
a toxic injury of the liver due to cannabis and the codeine syrup. In the next months bilirubin 
declined slowly to reach normal range but liver enzymes remained slightly elevated.  
Nearly a year later the patient presented again to his family doctor because of tonsillitis for 
which cefuroxime treatment was initiated. After three days of antibiotic therapy the patient 
stopped the medication because he felt healthy again. This lead to a relapse of the tonsillitis 
and simultaneously he developed marked jaundice with a severe pruritus and elevation of 
the AST, ALT, alkaline phosphatase and GGT. Viral hepatitis was once again excluded and a 
repeat ultrasound was still unremarkable. 
 A second liver biopsy was performed during this episode of cholestasis. There was still no 
sign of autoimmune hepatitis or evidence of chronic liver disease, other than persistence of 
chronic cholestasis (Fig. 2A). An immunohistochemical staining for BSEP (Fig 2B), MDR3 
(Fig 2C), and CD10 (Fig 2D) revealed correct localization of the proteins within the 
canalicular membrane of hepatocytes. However, BSEP protein expression was remarkably 
heterogenous and overall rather low.  (Fig. 2B). Based on the immunohistochemical results, 
the suspicion of a bile acid transporter disorder was raised. In addition drug-induced liver 
injury resulting in cholestasis due to the inhibition of the bile salt export pump was still a 
possibility.  
Meanwhile the patient received fat-soluble vitamins (vitamin A, D, E and K) and 
ursodeoxycholic acid. After a few weeks bilirubin, AST, ALT and GGT normalized. Alkaline 
phosphatase remained persistently above the upper limit of normal. But given his age this 
was probably still within normal range owing to bone growth/turnover. After normalization of 
the liver enzymes the patient improved substantially.  
Nearly a year later again, the patient suffered again from tonsillitis that was treated with 
amoxicillin-clavulanic acid. A few days later he developed a cholestatic jaundice with itching 
and normal GGT. These recurrent episodes of severe jaundice and itching, the last two 
triggered by an upper respiratory tract infection and treated with antibiotics were highly 
suggestive of benign recurrent intrahepatic cholestasis and the genes ATP8B1 
(NM_005603), ABCB11 (NM_003742.2), ABCB4 (NM_000443) and NR1H4 
(NM_001206977.1) were analyzed for known mutations. 
The results of the genetic analysis are summarized in Table 1 and in supplementary table 1. 
In total, 36 polymorphic variants were identified in the four analyzed genes. None of the 
variants had so far been found to be causative of PFIC or BRIC. None of the variants in 
NR1H4 and ABCB4 had been previously associated with intrahepatic liver disease. Of note, 
rs319436 and rs222581in ATP8B1 were both homozygous and have been described in a 
patient with BRIC 8. Rs2287622 (p.V444A; homozygous) in ABCB11 is known to be 
associated with lower protein levels of BSEP and an increased susceptibility to acquired 
cholestasis 9. Furthermore, p.A1028A (heterozygous in our patient) was found previously in a 
patient with BRIC8, in patients with PFIC210 and associated with primary intrahepatic 
stones11. In addition, rs414877, rs8632237 and rs497692 have been found in PFIC2 patients 
and rs497692 was found in a patient with BRIC 8.  
Taken together, and in line with the clinical findings, the variants in ABCB11 suggest a 
predisposition for “drug induced cholestatic liver injury” (DILI). While the clinical picture is 
compatible with BRIC, the variants identified in ABCB11 are common polymorphisms. 
However, the combination of the different polymorphisms together with the common ABCB4 
polymorphisms (R652G and I237I) may render the patient more susceptible to the 
development of cholestasis in response to infections and/or drug treatment. 
In order to obtain more information on the role BSEP and MDR3 in the pathogenesis of the 
cholestatic episodes, the interaction of the antibiotic cefuroxime with these two canalicular 
ABC-transporters using a newly established assay system 12 has been studied. Figure 3 


















Benign recurrent intrahepatic cholestasis (BRIC) is a rare autosomal-recessive disorder 
characterized by recurrent attacks of jaundice and pruritus with symptom-free intervals 
lasting months to years. Unlike progressive familial intrahepatic cholestasis (PFIC), another 
hereditary genetic liver disease, BRIC does not progress to end stage liver disease 13. 
Although Summerskill and Walsh first described the disease in 1959 14, until now only a few 
hundred cases have been described in literature 15. In 1969 Tygstrup developed diagnostic 
criteria for BRIC that included at least two episodes of jaundice separated by a symptom-free 
interval lasting several months to years, laboratory values consistent with intrahepatic 
cholestasis, severe pruritus secondary to cholestasis, liver histology demonstrating 
centrilobular cholestasis, normal intrahepatic and extrahepatic bile ducts confirmed by 
cholangiography and the absence of other factors known to be associated with cholestasis 16.  
Little is known about precipitating factors of the cholestatic attacks in BRIC. Although it is 
assumed that viral infections may be a trigger for an episodes of cholestasis in BRIC 17, this 
has not been reported for bacterial infections. Preceding the jaundice, our patient had two 
episodes of tonsillitis, both treated with antibiotics. However, a pathogen was not found, 
making a viral infection as likely as a bacterial infection. We postulate that the infection, 
whether viral or bacterial, acted as a trigger for the BRIC episodes in our patient. A drug-
induced trigger might also be possible and may have aggravated the syndrome. However, 
the patient received two different antibiotics (cephalosporin and a -lactam antibiotic) with 
nearly no known cross-reaction between both antibiotic groups18,19, which makes a reaction 
to both agents unlikely. Cefuroxime does not inhibit BSEP, MRP2 or MRP3, but causes an 
intermediate inhibition of MRP420 and as shown here has not effect on MDR3(Figure 3). 
Although Amoxicillin/clavulanic acid is the most common drug associated with DILI21, there is 
no inhibition of MDR3 activity12. Furthermore, amoxicillin does not inhibit any of the 
transporters and clavulanic acid does not inhibit BSEP22.  
 
The genetic analysis of four genes (table 1 and supplementary table 1) revealed a complex 
array of variants. The c.270C>T variant in ABCB11 is a synonymous variant (p.F90F) and 
has previously been described in two patients (heterocygous) of a Chinese cohort of children 
with intrahepatic cholestasis10. Its allelic frequencies is around 5 % in different populations. 
One of these patients in the Chinese cohort also presented with p.V444A (Homozygous) and 
p.A1028A (homozygous). We take this as strong indication that this combination of variants 
may contribute to BRIC in our patient. The p.V444A variant tends to lower protein expression 
and is well established to be a risk factor for various forms of acquired cholestatic liver 
diseases9 as exemplified for intrahepatic cholestasis of pregnancy23. The p.A1028A variant 
was found significantly more frequent in patients with primary intrahepatic stones in Chinese 
individuals11 and in an individual with intrahepatic cholestasis of pregnancy23. Importantly, 
this variant may also lead to aberrant splicing24. The p.R698H variant was identified in a 
patient with cholestatic hepatitis due to androgenic steroids and in a patient under the 
antibiotic trimethoprim-sulfamethaxol25. Taken together, the rather low BSEP staining 
intensity in the biopsy may be explained by the p.V444A and the p.A1028A variants found in 
our patient and together with the ATP8B1 variants can be indicative of BRIC2. The 
combination of all variants on the other hand may make this patient susceptible to drug-
induced liver injury. 
Interestingly, our patient is homozygous for c.711A in the ABCB4 gene, a synonymous 
variant which is associated with abnormal liver serum parameters in a large Icelandic 
cohort26. Of note, in a cohort of 35 pediatric subjects with idiopathic gallstones, 34 out of 35 
patients were homozygous for this variant and one patient heterozygous27. Finally, we point 
out that at the time of sequencing, analysis of the promoters as well as of the TJP2 gene 
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Figure 2A. The lobules show canalicular (arrow) and intrahepatocytic cholestasis 
(arrowhead), in the absence of disarray or of significant inflammation (Hematoxylin&Eosin, 










Figure 2B. BSEP expression shows a zonal pattern, retained in periportal areas (arrow) and 























Figure 3: A and B shows TCA transport after 24h incubation with drugs. Monolayers were 
treated with drugs for 24h and transport experiment were started by adding 10 uM TCA to 
the basolateral compartment. The effect was assessed by measuring the amount of TCA in 
the apical compartment after 30 minutes. Shown are two (A and B) independent experiments 
for 10 uM posaconazole and 100 uM cefuroxime, 1 experiment for 10 uM cefuroxime and 
WT. The intracellular TCA accumulation was assessed by measuring the amount of TCA 
from cell lysate, solubilized in 1% Triton X-100 
Figure 3 C: C6-NBD-PC secretation after 24h incubation with drugs. Monolayers were 
treated with drugs for 24h to assess their effect on MDR3-mediated C6-NBD-PC secretion. 
Shown are 3 independent experiments for 10 uM posaconazole and 4 experiments for 100 










rs number g. (GRCh38) c. p. AF (%) all / NFE / AFR 
NR1H4 (FXR)     
only non-coding variants     
ATP8B1 (FIC1)     
rs319438 (ho) 57697620A>G * 696T>C D232D 99.8 / 100.0 / 98.0 
rs319443 (ho) 57695300T>G * 811A>C R271R 99.7 / 100.0 / 97.2 
rs222581 (ho) 57650444T>C 3454A>G A1152T gDNA vs. transcript 
ABCB11 (BSEP)     
rs34313070 168973871del 1309-31del - 0.2 / 0.01 / 1.9 
rs4148777 169013391A>G 270T>C F90F 4.6 / 3.6 / 6.8 
rs2287622 (ho) 168973818A>G 1331T>C V444A 56.9 / 59.7 / 56.6 
rs138642043 168964291C>T 2093G>A R698H 0.4 / 0.3 / 0.7 
rs497692 168932506T>C 3084A>G A1028A 54.5 / 53.6 / 26.6 
ABCB4 (MDR3)     
rs2230028 87426860T>C 1954A>G R652G 10.5 / 7.5 / 34.8 
rs2109505 g.87450090T>A 711A #   
 
Detected common intronic variants are listed in Supplementary Table 1. 
AF: allele frequency; taken from Genome Aggregation Database (gnomAD), Cambridge, MA 
(http://gnomad.broadinstitute.org/) [allele frequencies accessed November 2018]. AFs are given for 
the worldwide (all), Non-Finnish European (NFE) as well as the African population (AFR). 
Variants are specified by rs number, exchange on genomic (g.) and coding (c.) DNA level and if 
applicable on protein level. 
Reference sequences:NR1H4: NM_001206977.1; ATP8B1: NM_005603.4; ABCB11: NM_003742.2, 
ABCB4: NM_000443.3 
* in alternative reference sequence AF038007 C-alleles are designated as the reference allele 




Supplementary Table 1 
rs number g. (GRCh38) c. p. AF (%) all / NFE / AFR 
NR1H4 (FXR)     
rs79934001 100536486C>A 733-26C>A - 2.7 / 0.2 / 26.2 
rs7138843 100536917T>A 832-31T>A - 12.3 / 2.1 / 45.6 
rs11110413 100536932T>A 832-16T>A - 4.2 / 0.4 / 36.0 
ATP8B1 (FIC1)     
rs1968274 57646979T>C *1509A>G - 25.4 / 20.9 / 28.6  
rs4940950 57647588C>A *900G>T - 46.5 / 48.2 / 37.8 
rs4306606 57667063G>A 2285+29C>T - 22.6 / 26.5 / 9.8 
rs317838 57671424G>A 1932+44C>T - 42.9 / 36.7 / 38.7 
rs317809 57691685G>A 1220+122C>T - 40.8 / 46.2 / 24.5 
rs319439 57697598G>A 698+20C>T - 48.0 / 47.3 / 26.4 
rs319442 (ho) 57695584G>A 699-52C>T - 99.7 / 100.0 / 97.1 
rs319438 (ho) 57697620A>G 696T>C D232D 99.8 / 100.0 / 98.0 
rs319443 (ho) 57695300T>G 811A>C R271R 99.7 / 100.0 / 97.2 
rs222581 (ho) 57650444T>C 3454G>A A1152T gDNA vs. transcript 
ABCB11 (BSEP)     
rs496550 168923202T>C *420A>G - 47.8 / 53.6 / 30.2 
rs495714 168923254C>T *368G>A - 47.7 / 53.5 / 30.2 
rs473351 168923386T>C *236A>G - 62.01 / 55.5 / 68.7 
rs579275 168923856T>C 3766-34A>G - 54.6 / 53.8 / 26.3 
rs853772 168958145G>T 2179-17C>A - 53.6 / 52.4 / 26.6 
rs34313070 168973871del 1309-31del - 0.2 / 0.01 / 1.9 
rs4148776 169014372A>G 99-18T>C - 8.4 / 5.5 / 31.0 
rs4148772 169018202C>T -27-50G>A - 5.3 / 3.8 / 6.1 
rs2193831 (ho) 168970367C>T 1639-152G>A - 56.7 / 59.7 / 55.9 
rs2241340 (ho) 168971815A>G 1638+32T>C - 57.1 / 59.8 / 56.4 
rs2287623 (ho) 168973645G>A 1434+70C>T - 57.2 / 59.0 / 55.8 
rs2287618 (ho) 168986299T>C 909-15A>G - 69.9 / 69.3 / 82.8 
rs4148777 169013391A>G 270T>C F90F 4.6 / 3.6 / 6.8 
rs2287622 (ho) 168973818A>G 1331T>C V444A 56.9 / 59.7 / 56.6 
rs138642043 168964291C>T 2093G>A R698H 0.4 / 0.3 / 0.7 
rs497692 168932506T>C 3084A>G A1028A 54.5 / 53.6 / 26.6 
ABCB4 (MDR3)     
rs45549641 87402374A>G 3655-72T>C - 13.5 / 8.6 / 27.5 
rs31653 87403297A>G 3508-16T>C - 87.7 / 89.5 / 97.7 
rs7788404 87418497T>C 2478+40A>G - 9.2 / 7.7 / 18.0 
rs31668 87423890G>A 2211+16C>T - 89.9 / 92.4 / 93.4 
rs1017054 87426695T>C 2064+55A>G - 15.2 / 8.6 / 33.5 




1. Hirschfield GM, Heathcote EJ, Gershwin ME. Pathogenesis of cholestatic liver disease and 
therapeutic approaches. Gastroenterology. 2010;139(5):1481-1496. 
2. Hirschfield GM. Genetic determinants of cholestasis. Clin Liver Dis. 2013;17(2):147-159. 
3. Kubitz R, Droge C, Stindt J, Weissenberger K, Haussinger D. The bile salt export pump 
(BSEP) in health and disease. Clin Res Hepatol Gastroenterol. 2012;36(6):536-553. 
4. van der Woerd WL, Houwen RH, van de Graaf SF. Current and future therapies for inherited 
cholestatic liver diseases. World J Gastroenterol. 2017;23(5):763-775. 
5. Gudbjartsson DF, Sulem P, Helgason H, et al. Sequence variants from whole genome 
sequencing a large group of Icelanders. Sci Data. 2015;2:150011. 
6. Gonzales E, Taylor SA, Davit-Spraul A, et al. MYO5B mutations cause cholestasis with 
normal serum gamma-glutamyl transferase activity in children without microvillous inclusion 
disease. Hepatology. 2017;65(1):164-173. 
7. Schady DA, Finegold MJ. Contemporary Evaluation of the Pediatric Liver Biopsy. 
Gastroenterol Clin North Am. 2017;46(2):233-252. 
8. Blackmore L, Knisely AS, Hartley JL, et al. Polymorphisms in ABCB11 and ATP8B1 
Associated with Development of Severe Intrahepatic Cholestasis in Hodgkin's Lymphoma. J 
Clin Exp Hepatol. 2013;3(2):159-161. 
9. Pauli-Magnus C, Meier PJ, Stieger B. Genetic determinants of drug-induced cholestasis and 
intrahepatic cholestasis of pregnancy. Semin Liver Dis. 2010;30(2):147-159. 
10. Hu G, He P, Liu Z, Chen Q, Zheng B, Zhang Q. Diagnosis of ABCB11 gene mutations in 
children with intrahepatic cholestasis using high resolution melting analysis and direct 
sequencing. Mol Med Rep. 2014;10(3):1264-1274. 
11. Pan S, Li X, Jiang P, et al. Variations of ABCB4 and ABCB11 genes are associated with 
primary intrahepatic stones. Mol Med Rep. 2015;11(1):434-446. 
12. Mahdi ZM, Synal-Hermanns U, Yoker A, Locher KP, Stieger B. Role of Multidrug Resistance 
Protein 3 in Antifungal-Induced Cholestasis. Mol Pharmacol. 2016;90(1):23-34. 
13. Putterman C, Keidar S, Brook JG. Benign recurrent intrahepatic cholestasis--25 years of 
follow-up. Postgrad Med J. 1987;63(738):295-296. 
14. Summerskill WH. The Syndrome of Benign Recurrent Cholestasis. Am J Med. 1965;38:298-
305. 
15. Luketic VA, Shiffman ML. Benign recurrent intrahepatic cholestasis. Clin Liver Dis. 
2004;8(1):133-149, vii. 
16. Tygstrup N, Jensen B. Intermittent intrahepatic cholestasis of unknown etiology in five young 
males from the Faroe Islands. Acta Med Scand. 1969;185(6):523-530. 
17. van Mil SW, van der Woerd WL, van der Brugge G, et al. Benign recurrent intrahepatic 
cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology. 2004;127(2):379-
384. 
18. Campagna JD, Bond MC, Schabelman E, Hayes BD. The use of cephalosporins in penicillin-
allergic patients: a literature review. J Emerg Med. 2012;42(5):612-620. 
19. Apter AJ, Kinman JL, Bilker WB, et al. Is there cross-reactivity between penicillins and 
cephalosporins? Am J Med. 2006;119(4):354 e311-359. 
20. Morgan RE, van Staden CJ, Chen Y, et al. A multifactorial approach to hepatobiliary 
transporter assessment enables improved therapeutic compound development. Toxicol Sci. 
2013;136(1):216-241. 
21. deLemos AS, Ghabril M, Rockey DC, et al. Amoxicillin-Clavulanate-Induced Liver Injury. Dig 
Dis Sci. 2016;61(8):2406-2416. 
22. Morgan RE, Trauner M, van Staden CJ, et al. Interference with bile salt export pump function 
is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 
2010;118(2):485-500. 
23. Keitel V, Vogt C, Haussinger D, Kubitz R. Combined mutations of canalicular transporter 
proteins cause severe intrahepatic cholestasis of pregnancy. Gastroenterology. 
2006;131(2):624-629. 
24. Byrne JA, Strautnieks SS, Ihrke G, et al. Missense mutations and single nucleotide 
polymorphisms in ABCB11 impair bile salt export pump processing and function or disrupt pre-
messenger RNA splicing. Hepatology. 2009;49(2):553-567. 
25. El Sherrif Y, Potts JR, Howard MR, et al. Hepatotoxicity from anabolic androgenic steroids 
marketed as dietary supplements: contribution from ATP8B1/ABCB11 mutations? Liver Int. 
2013;33(8):1266-1270. 
26. Gudbjartsson DF, Helgason H, Gudjonsson SA, et al. Large-scale whole-genome sequencing 
of the Icelandic population. Nat Genet. 2015;47(5):435-444. 
27. Jirsa M, Bronsky J, Dvorakova L, et al. ABCB4 mutations underlie hormonal cholestasis but 
not pediatric idiopathic gallstones. World journal of gastroenterology : WJG. 
2014;20(19):5867-5874. 
28. Bull LN, Thompson RJ. Progressive Familial Intrahepatic Cholestasis. Clin Liver Dis. 
2018;22(4):657-669. 
29. Reichert MC, Hall RA, Krawczyk M, Lammert F. Genetic determinants of cholangiopathies: 
Molecular and systems genetics. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4 Pt 
B):1484-1490. 
 
